Phase II Study of Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma: Hoosier Cancer Research Network LUN15-299
Latest Information Update: 17 May 2024
At a glance
- Drugs Nivolumab (Primary) ; Ramucirumab (Primary)
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
Most Recent Events
- 18 Apr 2024 Status changed from active, no longer recruiting to discontinued due to IRB Study Closure.
- 24 Oct 2023 Planned End Date changed from 1 Jun 2023 to 9 Nov 2023.
- 06 Feb 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Jun 2023.